Bone Healing News
-
CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material
CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels. Bone regeneration is one of the fastest growing research disciplines, given the massive impact it can have on ...
By CELLINK
-
Daxor Corporation Appoints Linda Cooper, Vice President Project Management
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. “Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda’s proven track record makes her an excellent addition to the Daxor team ...
-
HK inno.N licenses in mAbxience’s denosumab biosimilar
HK inno.N said it has signed an exclusive license agreement with Spain’s mAbxience to market the latter’s Prolia (ingredient: denosumab) biosimilar, a preventive treatment for osteoporosis and cancer-related skeletal complications, in Korea. Under the contract, HK inno.N will exclusively market two types of denosumab biosimilars – 60 mg and 120 mg — from mAbxience, and ...
By mAbxience
-
HEDIS OSW Helps Osteoporosis Patients and Early Detection
Osteoporosis is a disorder that causes the bone density to reduce with time, making bones so weak they get fractured even with a light fall. Regular testing has many benefits as it is tracked by HEDIS (Healthcare Effectiveness Data and Information) to ensure early detection among women to manage their condition properly. Read on to know ...
By BeamMed Inc.
-
Osteoporosis in Older Patients Easy Assessment Easy Assessment of Osteoporosis in Older Patients
According to the National Osteoporosis Foundation (NOF), about 54 million Americans suffer from osteoporosis, presenting low bone mass, and suffering from brittle-bone related injuries, such as fractures, and broken bones. In fact, the disease is responsible for “two million broken bones and $19 billion in related costs every year”, while by the year 2025, “experts predict that ...
By BeamMed Inc.
-
Testing Your Bone Density for Osteoporosis Awareness Month
Testing your bone density may not be a usual task on your priority list, but May serves as National Osteoporosis Month and can serve as a friendly reminder to check your bone density. Osteoporosis is a skeletal condition that affects far more women than it does men. Low bone mass puts you more at risk for osteoporosis, so regular and early bone density testing can greatly help you. Beam Med is a ...
By BeamMed Inc.
-
The Importance of Diagnosing Osteoporosis in Women
A widespread yet underrated medical condition, Osteoporosis is a bone disease seldom paid importance to in today’s world. In this condition, the bones are porous, meaning they lack density and contain holes – unlike the regular bone structure. This results in the bones becoming brittle and thus susceptible to injury and breakage. A simple fall that may not have been as harmful before ...
By BeamMed Inc.
-
Sunlight MiniOmni and Osteoporosis Fracture Prevention
Osteoporosis has become a public health issue worldwide. There are more than 200 million patients affected by the condition. Research has also suggested that around 33% of women over the age of 50 will experience a fracture caused by the presence of osteoporosis at some point. Furthermore, an estimated 30% of postmenopausal women will also develop this condition. The prevalence of osteoporosis ...
By BeamMed Inc.
-
Demand for Brisbane Medical Micro Screw Creates Waitlist Before Official US Launch
The Brisbane medical innovation of the world’s smallest cannulated compression screw by Field Orthopaedics is in high demand in 20 US states before it’s official launch at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting from March 12 to 16 in Las Vegas, USA. Hospitals and distributors in 10 US states have requested access to the product before its official launch ...
-
Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant’s PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as a ...
-
BOC Sciences: Peptides Open New Path toward Osteoporosis Treatment
BOC Sciences declares that some of its peptide products have been proven applicable for osteoporosis treatment, which is a significant contribution to the therapeutic areas. Bone tissue engineering and the research surrounding peptides have expanded significantly over the last few decades. Several peptides have been shown to support and stimulate the bone healing response and have been proposed ...
By BOC Sciences
-
Announcement – RSIP Vision Presents Successful Preliminary Results from Clinical Study of 2D-to-3D Knee Bones Reconstruction
RSIP Vision, an experienced developer of groundbreaking AI technologies for medical imaging, today reveals preliminary results from an ongoing clinical study for the evaluation of the reconstruction of a 3D knee model from 2D X-ray images at Assuta Medical Center in Tel Aviv. This tool is based on novel, patent-pending technology, implementing advanced artificial intelligence (AI) to produce an ...
By RSIP Vision
-
OSSIO Receives Vizient Contract for Bio-Integrative Orthopedic Fixation Technology
OSSIO, Inc., an orthopedic fixation technology company, today announced that it has received a contract with Vizient, Inc., making the company’s portfolio of bio-integrative OSSIOfiber products available at negotiated pricing to health care providers in Vizient’s group purchasing organization (GPO) under a three-year contract starting March 1. OSSIO’s contract with Vizient ...
By OSSIO Inc
-
OSSIO Awarded FDA 510(k) Clearance for OSSIOfiber Compression Screw Portfolio
OSSIO, Inc., an orthopedic fixation technology company, today announced that its OSSIOfiber® Compression Screw Portfolio has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for maintenance of alignment and fixation of bone fractures, comminuted fractures, fragments, osteotomies, arthrodesis and bone grafts of the upper extremity, fibula, knee, ankle and foot ...
By OSSIO Inc
-
Active Implants SUN Clinical Trial for Persistent Knee Pain Now Underway in San Diego
Active Implants, a company that develops orthopedic implant solutions, today announced that the company’s SUN (Safety Using NUsurface) trial is now underway in San Diego. Dr. Scott A. Hacker at Grossmont Orthopaedic Medical Group is the only physician in San Diego County – and the center is one of just 10 sites nationwide – participating in the SUN clinical trial to evaluate the ...
-
Alfa Chemistry Announces the Launch of Extracted Peptides
Demonstrating competence in peptide R&D, production, and sales integration, the US-based chemical supplier Alfa Chemistry recently announced the launch of its peptide product line for researchers across the globe. After this move, a wide range of high-quality extracted peptides, including hydrolyzed protein peptides, fish collagen peptides, marine fish oligopeptides, oyster peptides, sea ...
-
CurvaFix Announces Participation in Orthopaedic Trauma Association Industry Sessions
BELLEVUE, Wash., Oct. 6, 2022 – CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced participation in the Industry Sessions of the Orthopaedic Trauma Association (OTA) 38th Annual Meeting, Oct. 12-15 in Tampa, Fl, highlighting the expanding use of the CurvaFix® IM Implant by industry-leading surgeons for both fragility and high-impact ...
-
Field Orthopaedics announces strategic alliance with Medartis Inc
The strategic alliance will see the NX Nail system from Field Orthopaedics added to Medartis’ comprehensive hand portfolio in an exclusive distribution partnership, which will extend the global distribution footprint of the product and provide growth opportunities in international markets. With an anatomically inspired head, narrow waist and cutting efficiency, the NX Nail is engineered to ...
-
CurvaFix Announces Participation in Orthopaedic Trauma Association Industry Sessions
BELLEVUE, Wash., Sept. 28, 2022 – CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the addition of three new members to its Surgeon Advisory Board. The new members bring together expertise in orthopedic traumatology, pelvis and acetabular trauma reconstruction, and Fragility Fractures of the Pelvis (FFP) to support CurvaFix’s focus on ...
-
LaunchPad Medical Wins a $2.5 Million NIH Grant to Improve Cranial Procedures
LaunchPad Medical, Inc. announced that it has been awarded a $2.5 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant (1R44NS115386) from the National Institute of Neurological Disorders and Stroke to advance the development of Tetranite®, its bone adhesive biomaterial technology, to improve cranial flap fixation procedures. The clinical use of this product is expected ...
By RevBio Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you